Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence

INTRODUCTION: To analyze the efficacy and safety profile of the intravitreal ranibizumab biosimilar molecule, Razumab(®) (Intas Pharmaceuticals, Ahmedabad, India; BRm; Razumab(®)) and the innovator ranibizumab drug (IRm; LUCENTIS(®)) in Indian patients with polypoidal choroidal vasculopathy (PCV) un...

Descripción completa

Detalles Bibliográficos
Autores principales: Soman, Manoj, Nair, Indu, Sheth, Jay U., Nair, Unnikrishnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114250/
https://www.ncbi.nlm.nih.gov/pubmed/35412266
http://dx.doi.org/10.1007/s40123-022-00507-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114250/
https://www.ncbi.nlm.nih.gov/pubmed/35412266
http://dx.doi.org/10.1007/s40123-022-00507-w

Ejemplares similares